Abbott has announced that they have received FDA approval for their new ablation catheter for atrial fibrillation – TactiCath™
The approval of the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™, can help more physicians integrate ablation with 3D mapping to advance the treatment of atrial fibrillation.
Abbott has announced U.S. Food and Drug Administration (FDA) approval of the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™, a new ablation catheter designed to help physicians accurately and effectively treat atrial fibrillation (AFib).
The approval further expands Abbott’s portfolio of cardiac ablation tools that integrate with the company’s EnSite Precision™ cardiac mapping system to help physicians develop more precise images of the heart during cardiac ablation procedures.
Similar to Abbott’s other sensor enabled mapping and ablation treatment catheters, TactiCath (Sensor Enabled) SE delivers more precise images of the heart overlaid with real-time electrical activity information. The catheter also utilises the advanced ergonomic design found in the company’s FlexAbility™ ablation catheter for superior reach and manoeuvrability during cardiac ablation procedures.
One of the most common cardiac arrhythmias in the world, AFib can affect how efficiently the heart pumps blood through the body, causing symptoms such as dizziness, shortness of breath or lightheadedness. The condition can also increase a person’s risk of stroke. To treat conditions like AFib, physicians can use ablation catheters to scar tissue in the heart that is generating abnormal electrical signals and disrupting a patient’s natural heartbeat. As the number of patients receiving cardiac ablation therapy worldwide has grown, Abbott has prioritised ablation technology that adds efficiency and accuracy to ablation procedures. Abbott cardiac ablation technology is currently used to treat patients in more than 84 countries worldwide.
Not all ablation technology is the same, however. Physicians have begun exploring the use of new tools such as “contact force” technology during ablation procedures to help them avoid applying too much pressure to heart tissue (resulting in complications) or insufficient pressure (which may reduce the effectiveness of the procedure). In addition, Abbott has also invested in technology to improve the accuracy of cardiac mapping to support cardiac ablation procedures.
Over the last two years, Abbott has expanded offerings within its electrophysiology portfolio to drive new growth and build on the company’s leadership. In addition to new clinical trials to further build clinical evidence surrounding cardiac ablation, the company has also launched the Advisor™ HD Grid Mapping Catheter, Sensor Enabled, and the FlexAbility™ Ablation Catheter, Sensor Enabled.
Roger Winkle, M.D., an electrophysiologist at Sequoia Hospital in Redwood City, Calif., and one of the first physicians to treat patients with the newly FDA-approved catheter said, “Cardiac ablation has become a front-line therapy in the fight against conditions like atrial fibrillation in part because of improvements to the technology available today. The Abbott TactiCath SE ablation catheter represents one of those major improvements, and offers an incredibly powerful, yet easy to use, combination of advanced technologies to improve ablation procedures.”
Srijoy Mahapatra, M.D., FHRS, medical director of Abbott’s Electrophysiology business said, “TactiCath SE directly supports our goal of supporting fast, effective and safe cardiac ablation procedures. As more physicians turn to cardiac ablation to treat AFib, Abbott’s goal is to equip them with the most advanced ablation catheters combined with the most advanced cardiac mapping on the market.”
In 2018 Acesion released news of positive results for novel drug targeting atrial fibrillation.